Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06618079 | Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B | PHASE1 | ACTIVE NOT_RECRUITING | 46 | — | — | Apr 20, 2024 | Oct 1, 2024 | Oct 1, 2024 | 1 | South Korea |
Pharmacokinetic parameter
Pharmacokinetic parameter
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Evaluate the effect of S-Amlodipine on the pharmacokinetic properties of Azilsartan under steady states. |
| Cohort B | EXPERIMENTAL | Evaluate the effect of Azilsartan on the pharmacokinetic properties of S-amlodipine under steady states. |
| Name | Type | Description |
|---|---|---|
| HUC2-565-A, HUC2-565-A and HUC2-565-B | DRUG | Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days. |
| HUC2-565-B, HUC2-565-A and HUC2-565-B | DRUG | Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days. |
\[ Inclusion Criteria \] 1. Healthy adult volunteer aged 19 years or older at the pre-study(screening) 2. Volunteer with a body mass index(BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less, with a 50kg or more weight at the pre-study(screening) 3. A person who has no chronic disease requiring birth...